AP
TLX

Aspect Partners’s Telix Pharmaceuticals TLX Stock Holding History

Aspect Partners’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62K Buy
401
+21
+6% +$214 ﹤0.01% 430
2026
Q1 		$3.64K Buy
380
+28
+8% +$213 ﹤0.01% 407
2025
Q4 		$2.64K Buy
+352
New +$3.39K ﹤0.01% 475

Other funds holding TLX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Aspect Partners's TLX Position: Q2 2026 in Review

Aspect Partners increased its Telix Pharmaceuticals (TLX) stake by 5.5% in Q2 2026, buying an estimated $214 and bringing the position to 401 shares worth $4.62K. The position accounts for ﹤0.01% of the portfolio, ranked #430.

Aspect Partners first reported a position in TLX in Q4 2025 and has held it in 3 quarters since. 9 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Aspect Partners held 401 shares of Telix Pharmaceuticals worth $4.62K as of Q2 2026.
  • Aspect Partners bought 21 Telix Pharmaceuticals shares in Q2 2026, an estimated $214.
  • Telix Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #430 holding.
  • Aspect Partners first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 9 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.